Forced vital capacity in idiopathic pulmonary fibrosis--FDA review of pirfenidone and nintedanib.

N Engl J Med

From the Division of Pulmonary, Allergy, and Rheumatology Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD.

Published: March 2015

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMp1500526DOI Listing

Publication Analysis

Top Keywords

forced vital
4
vital capacity
4
capacity idiopathic
4
idiopathic pulmonary
4
pulmonary fibrosis--fda
4
fibrosis--fda review
4
review pirfenidone
4
pirfenidone nintedanib
4
forced
1
capacity
1

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!